Canada markets open in 3 hours 57 minutes

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.6600-0.0300 (-1.78%)
At close: 03:59PM EDT

Theratechnologies Inc.

2015 Peel Street
11th Floor
Montreal, QC H3A 1T8
Canada
514 336 7800
https://www.theratech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees103

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul LévesquePresident, CEO & Director1.6MN/A1965
Mr. Philippe Dubuc M.B.A., MBASenior VP & CFO585.67kN/A1967
Mr. Jocelyn Lafond L.L.M., LL.B.General Counsel & Corporate Secretary428.5kN/A1968
Dr. Christian Marsolais Ph.D.Senior VP & Chief Medical Officer588.78kN/A1963
Mr. John LeasureGlobal Commercial Officer570.22kN/A1965
Hon. Andre Dupras M.Sc.Vice President of Human ResourcesN/AN/A1964
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Corporate Governance

Theratechnologies Inc.’s ISS Governance QualityScore as of March 1, 2024 is 5. The pillar scores are Audit: 7; Board: 2; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.